Companies › Taysha Gene Therapies
1 active drug program in 3 registered trials: 2 Phase 3, 1 Phase 1; Neurology, Psychiatry; next expected readout Nov 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| TSHA-102 recombinant, non-replicating, self-complementary AAV9 vector encoding miniMECP2 gene, deli | MECP2 | Phase 3 | Rett Syndrome | Nov 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06152237 | TSHA-102 | Phase 1 | Rett Syndrome | Psychiatry | Nov 2028 |
| NCT07480564 | TSHA-102 | Phase 3 | Rett Syndrome | Neurology | Jun 2031 |
| NCT05606614 | TSHA-102 | Phase 3 | Rett Syndrome | Neurology | Jun 2031 |
Cash of $455m on 2026-06-30; operating cash outflow about $165m a year; runway about 33 months at that burn, to Apr 2029; 0 of 2 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 12 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Neurogene Dyne Therapeutics Stoke Therapeutics Capricor ProofPilot
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.